Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 24 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NFnDe3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXfsWIt6OC1yLkWg{txO NHj1TIwzPCCq NXHvcHZ4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M3rhb|I2PjZ|N{[5
HepG2-HBV1.1 MlnIRZBweHSxc3nzJGF{e2G7 M{nQUVAuOC53IN88US=> MYSyOEBp NVOwUY8zcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M4rKVlI2PjZ|N{[5
HepG2.2.15 NUDjV|lUTnWwY4Tpc44hSXO|YYm= Ml;GNE4yKM7:TR?= MYCyOEBp MYHwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= MknaNlU3PjN5Nkm=
HepG2-HBV1.1 NVfFUIhyTnWwY4Tpc44hSXO|YYm= MXewMlEh|ryP M2e2PVI1KGh? M2HOU5Bzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> MkniNlU3PjN5Nkm=
HepG2-HBV1.1 MWHGeY5kfGmxbjDBd5NigQ>? NXfBRXhnOC5zIN88US=> MVK0PEBp Mn3ydJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ NEjXUnEzPTZ4M{e2PS=>
HepG2-HBV1.1 NEX1W|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjCe3AxNjFizszN NIPWb4gyNTViZB?= MUPpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 NG\heJczPTZ4M{e2PS=>
HepG2-HBV1.1 M4DLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfDNE4yKM7:TR?= NHqxdVQyNTViZB?= NYW5dHFbcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> M1TBcFI2PjZ|N{[5
HepG2-HBV1.1 M1[5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jqRVAvOSEQvF2= NVfZNXQ3OTJvN{KgbC=> NHvhcFFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> NEHQZ4IzPTZ4M{e2PS=>
HepG2-HBV1.1 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS3bG5JOC5zIN88US=> M{\PZlEzNTd{IHi= MUnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= MlvrNlU3PjN5Nkm=
Raji NFPPfYxHfW6ldHnvckBCe3OjeR?= MUSwMlXDqM7:TR?= NHvoO|A4OiCq MXrhZo9tcXOqZYOgZZV1d3CqYXf5xsA> M1POelI2PDR4M{e3
SK-MEL-28  MnGwSpVv[3Srb36gRZN{[Xl? MlLJN|Ahdk1? M13VcVYhcA>? NFLndXlqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= MXiyOVMyOzBzMB?=
H157 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rONWlEPTB;MT6wN{DDuSByLkC0JI1qfTKP MX2yOVI2PzlzMR?=
Jurkat M3ThZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxMVMhdk1? NXThfFF3PDkEoHi= M2rlb2ROW09? NXzDXZdx\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NU\mb20{OjVzNU[xOFY>
CEM Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jBN|EuOyCwTR?= MVG0POKhcA>? NUDlSIVJTE2VTx?= M3zzZ4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NHXie3czPTF3NkG0Oi=>
P12 NUjKXVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxMVMhdk1? MnfvOFjDqGh? M1;0[GROW09? NInid41l\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MXGyOVE2PjF2Nh?=
KB NYDLOlVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\0WZNKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN NHvRPI0zPTB3OEWyOi=>
KBv200 (ABCB1) NVTveoszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLKTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= MV2yOVA2QDV{Nh?=
SUDHL6  M4XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxNgKBkc7:TR?= NGjlZ3Q1QC95MjDo NHzObldqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MYCyOFk3OTZyNB?=
SUDHL6  NVHkZWs{TnWwY4Tpc44hSXO|YYm= NX;6UHdkOeLCid88US=> NFXTSYw4OiCq NFnweXVqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D NFrhOGYzPDl4MU[wOC=>
HCT-116 NXXTVoFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnHTVUxRTVibl2= M4[4RlI1QTJ5OEW3
SKNBe2C M{nyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL2TWM2OD1|Mj64xtE1NjBibl2= MWqyOFkzOTl{MB?=
IGNR91 M{j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\pdWlEPTB;MkSuN:KyOS55IH7N NEXHPZIzPDl{MUmyNC=>
SKNAS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfJPYhKSzVyPUGuOeKyOC5{IH7N NF3DbZEzPDl{MUmyNC=>
LAN1 M1;JZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwM9MxNE4zKG6P M1LhSFI1QTJzOUKw
SHSY5Y NYG4fIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMTWM2OD16LkNCtVAvPiCwTR?= NXP2TVhPOjR7MkG5NlA>
A549-WT NUm0bVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLYTWM2OD1zOT60N|chyrFiMD61PVQhKG6P NVvrc|FpOjR6NUi4Nlc>
A549-R NUXicZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C2fWlEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= NXnR[lZoOjR6NUi4Nlc>
MCF-7-WT M3fEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e3O2lEPTB;MUeuO|UzKMLzIECuNlE5KCCwTR?= NUHC[5NHOjR6NUi4Nlc>
MCF-7-R MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfqTWM2OD13LkWzPUDDuSByLkG0OEAhdk1? NUOwe4pPOjR6NUi4Nlc>
A549-R NYf4c|FyS3m2b4TvfIlkcXS7IFHzd4F6 NIC0OXNKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= MXyyOFg2QDh{Nx?=
MCF-7-R MUDDfZRwfG:6aXPpeJkhSXO|YYm= Mom5TWM2OD13LkWzPUDDuSByLkG0OEBvVQ>? NFX5Xo8zPDh3OEiyOy=>
SW620 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPZfVBKSzVyPUeuPFAhyrFiMD6wPEBvVQ>? MVSyOFczPjd|OR?=
SW620/AD300 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewVGlEPTB;OUC5MlYxKMLzIEiuPVEhdk1? NGKzRYUzPDd{NkezPS=>
HEK293/pcDNA3.1 NGLsOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwNEWgxtEhOC5{MDDuUS=> NHXteVEzPDd{NkezPS=>
HEK293/ABCC1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe1bZVKSzVyPUG5MlI6KMLzIEKuNFghdk1? MoTUNlQ4OjZ5M{m=
TCC NGPYUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPNXo4zPCCq NXP5PYlNUUN3ME23NEBvVQ>? M4m4SFI1PzF4OUS0
TCC NIPK[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq0PEBp NHvIboJKSzVyPUWwJI5O MUWyOFcyPjl2NB?=
HepG2/ADM M3TyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK4fWVKSzVyPUKuO|g3O8LzMD6yN|cyKM7:TR?= NETBU3ozPDdyNEW1Oi=>
HepG2 NFX3O4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe4OpVLUUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2= MWWyOFcxPDV3Nh?=
MCF-7/ADR NFW2TnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;EXI82UUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2= NXjnb4hrOjR5MES1OVY>
MCF-7 NYj0O5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TufmlEPTB;MD6wNVU6yrFyLkCwOlIh|ryP MWiyOFcxPDV3Nh?=
A-172  MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3wOXlIOC5zwrFOwG0> MlzXNlQwPzJiaB?= MmXEbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> M1rQXVI1PTNyMkO1
U-251MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGwMlHDqM7:TR?= NGjUR3MzPC95MjDo NILlXZhqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MmPENlQ2OzB{M{W=
DLD-1 NV7RUG46TnWwY4Tpc44hSXO|YYm= MkOyNVAxKG6P MnnCOFghcA>? M{H0VZBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? MoDkNlQ1ODN2NUO=
CCD18Co NI\Q[|NHfW6ldHnvckBCe3OjeR?= MmfoNVAxKG6P MWm0PEBp M4nidJBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? M3rKdFI1PDB|NEWz
DLD-1 NHzDWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjrNE0yODByIH7N MmfrOFghcA>? NGXubmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M2CxN|I1PDB|NEWz
CCD18Co NXTjXXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOzbnluOC1zMECwJI5O MlrrOFghcA>? Mne0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NF;kWowzPDRyM{S1Ny=>
HepG2 NH70[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm0TGxzOjRiaB?= M2TXPGlEPTB;NUKuOgKBkc7:TR?= M2rtW|I1OzRzNki4
HEK293/pcDNA3.1 M{\qVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHGNplKSzVyPUCuNFA1yrFyLkCwNFMh|ryP NFHMTmwzPDJ6NEe4Ny=>
HEK293/MRP1 NHrjZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEW1xtExNjBzMkCg{txO MX:yOFI5PDd6Mx?=
Ramos NELFT|RCeG:ydH;zbZMhSXO|YYm= MX2y5qCK|ryP MXG0PEBp Mnq1bY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{ NXPtXYpVOjR{NU[0PVE>
NCI-H1299/pcDNA3 MlfvR4VtdCCYaXHibYxqfHliQYPzZZk> NYjiT202OC1{MDDuUS=> NVnhNVlHQTZiaB?= NUXqNJlOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NVLIbY9yOjRzN{ewNVI>
H1299/ICAM-3 M4r1OWNmdGxiVnnhZoltcXS7IFHzd4F6 MnnGNE0zOCCwTR?= NEXaSGk6PiCq MkmwbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MnrJNlQyPzdyMUK=
NCI-H1299/pcDNA3 Mlm3SpVv[3Srb36gRZN{[Xl? NYLSWGtROS93L{GwM|IxyqCwTR?= M3f0cFk3KGh? NGiyWHhqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MUmyOFE4PzBzMh?=
H1299/ICAM-3 NYTtNok4TnWwY4Tpc44hSXO|YYm= M4jZR|EwPS9zMD:yNOKhdk1? M{DiTVk3KGh? NVTI[XRucW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M3HXflI1OTd5MEGy
W1 NGTySnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O5dGlEPTB;MD6wNFMzKM7:TR?= Mm\rNlQyPDBzN{[=
W1VR NHfQcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEW2JO69VQ>? MkPCNlQyPDBzN{[=
K562 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\wTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP NX7CWmhiOjRzM{W5N|c>
K562/ADR Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GxfWlEPTB;Mz6yOlEhyrFiMD60NVIh|ryP NXLGd2RLOjRzM{W5N|c>
K562 NHvCeJVCeG:ydH;zbZMhSXO|YYm= MnnFNE4{KM7:TR?= M4rJV|I1KGh? MkCxbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MWmyOFE{PTl|Nx?=
K562/ADR NFLwOIlCeG:ydH;zbZMhSXO|YYm= NV\6XotKOyEQvF2= NHvKT3YzPCCq MU\pcoR2[2W|IHHwc5B1d3Orcx?= MUOyOFE{PTl|Nx?=
A549 NIXPS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXywU5dSUUN3ME2wMlExKMLzIECuNFMh|ryP NVnv[2pDOjN7N{GwO|U>
K562 NFvWdVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmLkN{44PeLCk{[wxsBvVQ>? Mn\MO|LDqGkEoB?= Mmn2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MlXwNlM5Pzd{MkO=
lucena NUHQc2ZbS2WubDDWbYFjcWyrdImgRZN{[Xl? M3XL[FMvPzYkgKO2NOKhdk1? NYWxepA{PzMEoHlCpC=> M2XVWY5wKGWoZnXjeC=> NVXrNoJqOjN6N{eyNlM>
FEPS NITHSG9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVOzMlc26oDVNkFCpI5O MY[3NuKhcMLi M2TDc45wKGWoZnXjeC=> MXWyN|g4PzJ{Mx?=
A2780 NUToWGdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXmOY5OUUN3ME2zMlUhdU1? NUHpcHViOjN6MkmyNFM>
ACHN M1voWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRDBwMTDtUS=> NUjHUYF4OjN6MkmyNFM>
U-937 NHviRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLyRXRvUUN3MEyzOEBvVQ>? NF7KWWIzOzh{OUKwNy=>
Jurkat MU\BdI9xfG:|aYOgRZN{[Xl? NHPqepQ2yqEQvHevcYzDqA>? MYKyOEBp MlvYbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? M3XTfVI{QDFyNEC5
Jurkat MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC1xsDPxGdxbX|CpC=> M1XHdlI1KGh? MmPPZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn NULw[HhiOjN6MUC0NFk>
Hep-2 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDSTWM2OD1yLkC0xtExNjBzIN88US=> M1nuO|I{PzhyNEK0
Hep-2/v NGnQ[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3hSWJyUUN3ME2xMljDuTBwMkCg{txO MnGzNlM4QDB2MkS=
SGC-7901 NETteWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;yNE0yOCEQvHevcYw> NGjlVnUzPC92OD:3NkBp NXHofHZScW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz M1zadVI{PzR|NUey
SGC-7901/VCR NXS0VXBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX3WplVOC1zMDFOwIcwdWx? M13U[|I1NzR6L{eyJIg> NFrScGhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MWqyN|c1OzV5Mh?=
SGC-7901 NF;we3dCeG:ydH;zbZMhSXO|YYm= NUC0c2F1cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M2T0VVI{PzR|NUey
SGC-7901/VCR Mn;oRZBweHSxc3nzJGF{e2G7 NIfHepNqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NWPydo1DOjN5NEO1O|I>
KB-3-1 M{LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nXO2lEPTB;MT62OkDDuSByLkG2NkDPxE1? NYLUOJRvOjN4N{O0OFU>
KB-C2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fHOWlEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2= NHm3TGkzOzZ5M{S0OS=>
KB-3-1 NI\SXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTT|N5UUN3ME2xMlI3KMLzIECuNFI4KM7:TR?= M{LjT|I{Pjd|NES1
KB-V1 NYHidWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEflSHVKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?= MnHqNlM3PzN2NEW=
HEK293/pcDNA3.1 M375XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TmdmlEPTB;MkSuNUDDuSByLkKwOEDPxE1? MVqyN|Y4OzR2NR?=
HEK293/ABCB1 M1jSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjWZoVKSzVyPUO1NVIvQCEEsTCzO|gvOzlzIN88US=> MVmyN|Y4OzR2NR?=
A549/EGFP  Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DUWVAvODFvMUCwNEDPxE1? MnjwTWM2OD16Nj63JOKyKDJ7LkGg{txO NUHXVJB{OjN4M{SyPFI>
A549/Slug NVq2UYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XUUVAvODFvMUCwNEDPxE1? MlHaTWM2OD17LkegxtEhOy5zIN88US=> NU\iZlF6OjN4M{SyPFI>
JFCR39  NEC0dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxJOK2VQ>? MnLRNlQhcA>? M3rwOmROW09? MkXqcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? MWWyN|U6QDJ5Nh?=
A549 NYLMeII2TnWwY4Tpc44hSXO|YYm= MlfTNVAxKG6P MoLSNVYhcA>? NUT3RmRrTE2VTx?= M{\WWoxm[WS|IITvJIEhdG:|czDv[kBucWO{b4T1ZpVt\XN? M1W0elI{PTl6Mke2
SGC7901 NFy0TG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLmV|A5UUN3ME2xMlI36oDLwsJihKkxNjFzIN88[{9udA>? MX:yN|U3PDR6Mh?=
SGC7901/LV-NC MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn2PJBGUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? MYSyN|U3PDR6Mh?=
SGC7901/LV-SGO1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fuS2lEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw> NXXXWYxYOjN3NkS0PFI>
SGC7901/VCR M{C1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3LXGJKSzV|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>? NW\0OWJROjN3NkS0PFI>
SGC7901/VCR-NC MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHwTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> MXGyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s NYmzN5k6OjN3NkS0PFI>
SGC7901/ADR MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHhTWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> M1KwNFI{PTZ2NEiy
SGC7901/ADR-NC M2rFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwOURihKnDueLCiUCuOlgh|rypL33s Mn60NlM2PjR2OEK=
SGC7901/ADR-si-SGO1 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jCeGlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> MXqyN|U3PDR6Mh?=
SH-SY5Y  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnBcpExNjByMT2xNEDPxE1? M1\vT|I1KGh? MmXzTWM2OD1yLkGxN:KyOC5yMUKg{txO NFj3NIczOzF{OUC2OS=>
SH-SY5Y  NYf4[HRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m2d|AvODBzLUGwJO69VQ>? NHfSPHA1QCCq MUTJR|UxRTBwMEe4xtExNjByOTFOwG0> M1XFXlI{OTJ7ME[1
SH-SY5Y  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuwMlAxOS1zMDFOwG0> MVO3NkBp NU\NR|duUUN3ME2wMlA2OcLzMD6wNFgh|ryP MWWyN|EzQTB4NR?=
SH-SY5Y MYHBdI9xfG:|aYOgRZN{[Xl? NEi2TWoxNjFizszN NIXOdWYxNTJ2IHi= M3vjeolv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl NFS2VYczOzF{OUC2OS=>
SH-SY5Y M2XweGFxd3C2b4Ppd{BCe3OjeR?= NFrPfnoxNjFizszN M1TsSFAuOjRiaB?= NIOwNFVqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC= Mn\1NlMyOjlyNkW=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID